企業プロフィール
Scholar Rock 株価・ニュース・カタリスト
- ティッカー:
- SRRK
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
52.05 USD (-0.89%)
終値
最終更新: 2026年8月17日
5.35B USD
時価総額
株価変動の要因
The latest company update was “Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. SRRK changed 0.89% and closed at $52.05 on Aug 17, 2026, indicating a relatively limited closing-price reaction to this company update.
企業概要
Myostatin Biology
Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways.
Apitegromab
Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal muscular atrophy. It is designed as an add-on to therapies that address the underlying genetic cause.
Additional Pipeline
Scholar Rock is applying its platform to additional neuromuscular and metabolic indications where modulation of muscle biology may provide clinical benefit.
今後のカタリスト
- FDA action on the apitegromab BLA by September 30, 2026.
- Potential U.S. launch of apitegromab immediately following approval.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。